Gemella haemolysans is a rare pathogen in cases of bacterial meningitis. We present a case of meningitis due to G. haemolysans in a 17-month-old boy. This is the first reported case of Gemella meningitis in a child. The patient completely recovered following intravenous therapy with linezolid and chloramphenicol.
day) and cefotaxime (200 mg/kg/day) as part of our clinical protocol. Dexamethasone (0.6 mg/kg/day, 4 days) was given intravenously before the first administrated antibiotic dose. The CSF specimen was cultured on 5% sheep blood, eosinmethylene blue, and chocolate agars at 35°C in 5 to 10% CO 2 for 48 to 72 h. Because of a suspicion of endocarditis, three pairs of aerobic and anaerobic blood cultures, with each bottle containing 1 to 2 ml of the patient's blood, were obtained prior to initiation of antimicrobial therapy. The blood cultures were incubated in a BACTEC 9120 instrument (Becton Dickinson and Company, Sparks, MD). The urine specimen was cultured on 5% sheep blood eosin-methylene blue at 35°C in 5 to 10% CO 2 for 24 to 48 h. Blood and urine cultures were negative, but in CSF cultures on sheep blood and chocolate agars, small, grayish colonies, 10 2 CFU/ml, grew after 72 h. Colonies were weakly alpha-hemolytic on sheep blood agar. Gram staining of the colonies showed gram-variable cocci. The standard conventional biochemical method (15) and the API 20 STREP identification system (bioMérieux, Marcy l'Étoile, France) were used to identify these colonies. The organism was nonmotile and oxidase, catalase, and bile esculin reaction negative and failed to grow in broth containing 6.5% NaCl. In the API 20 STREP system, the isolate gave biotype number 040011011000 with a probability of 99.5%, which was interpreted as "very good identification." All tests showed that Gemella haemolysans was present in the CSF culture. Antimicrobial susceptibility testing was performed by the Kirby-Bauer disk diffusion method with Mueller-Hinton agar supplemented with 5% sheep blood and incubation in 5% CO 2 at 35°C (20) . The susceptibility of the isolate to antimicrobial agents was determined by applying the Clinical and Laboratory Standards Institute susceptibility criteria used for viridans group streptococci (4). The isolate was resistant to penicillin, ampicillin, ceftazidime, ceftriaxone, clindamycin, levofloxacin, and vancomycin (zone diameter, 14 mm) and susceptible to linezolid and chloramphenicol (Oxoid Limited, Hampshire, England) by the disk diffusion method. After the antimicrobial susceptibility test, intravenous administration of linezolid (100 mg/kg/day) and chloramphenicol (20 mg/kg/day) was started on day 4 as a substitute for ampicillin and cefotaxime. An Etest was performed while disk diffusion results were obtained. Later, we determined the vancomycin MIC by the Etest method according to the manufacturer's (AB Biodisk, Solna, Sweden) recommendations and found that the organism was susceptible (MIC, 1 g/ml) but we did not change the treatment protocol.
The patient's clinical status progressively improved. Fortyeight hours after initiation of linezolid and chloramphenicol treatment, the patient became afebrile. A subsequent CSF culture on day 6 was negative. After antibiotic treatment for 10 days, the patient's clinical status was excellent, his inflammatory indexes were normal, there was no evidence of neurologic sequelae, and his hearing was normal.
G. haemolysans was first described by Thjötta and Böe as Neisseria haemolysans in 1938. Berger further showed that it was catalase and oxidase negative and attacked carbohydrates fermentatively, unlike neisseriae. He considered that it should be allocated to a new genus, Gemella (little twin), within the family Neisseriaceae, with a single species, G. haemolysans. Nucleic acid hybridization studies showed no relatedness to members of the family Neisseriaceae. On the basis of these findings, the genus Gemella was transferred to the family of Streptococcaceae (7, 13, 14, 21) . G. haemolysans is a commensal organism of the upper respiratory, gastrointestinal, and genitourinary tracts of humans (7, 14) . However, as an opportunistic pathogen, G. haemolysans occasionally causes severe localized and generalized infections. Endocarditis (7, 8) , central nervous system infections (1, 9, 12, 13, 16), eye infections (17), spondylodiscitis (11) , thorax empyema (6), and bacteremia (22) have been described. Endocarditis is the most common infection caused by this organism (7, 8) . However, we did not find any clinical signs associated with endocarditis or any sign of endocarditis on echocardiography. Also, all of the blood cultures were negative. Interestingly, the infection site was the central nervous system, not the heart, in our case. Central nervous system infection due to G. haemolysans is very rare. To date, worldwide, there have been six documented cases of meningitis and a case of brain abscess due to G. haemolysans.
Characteristics of previously reported cases of intracranial infections due to G. haemolysans are summarized in Table 1 . The most common primary septic sites in the cases of intracranial Gemella sp. infections were the upper respiratory tract and the oral cavity (9, 10, 12, 16, 19) . In the present case, the portal of entry of the infecting organism is uncertain.
Infections caused by G. haemolysans in the pediatric age group are rare. In a Medline research, we found only three pediatric cases and none of them involved the central nervous system (Table 2) .
Generally, human infections caused by Gemella species are associated with underlying conditions, including an immunocompromised state, cancer, heart disease, sinusitis, or poor dental health, as well as with previous invasive medical procedures. Some cases have been reported in immunocompetent patients and have even caused life-threatening conditions in previously healthy people (7, 11) . In our case, the patient had an underlying chronic heart disease without a source of infection.
Infections due to G. haemolysans have been observed infrequently. During gram staining, cells are easily decolorized and may therefore appear gram variable or even gram negative; also, identification of the organism may be delayed owing to its slow growth and fastidious requirements. It is likely that gramstaining abnormality and morphological polymorphism are responsible for the misidentification of Gemella spp. They may be alpha-hemolytic on blood agar and catalase negative and appear as gram-positive cocci. Therefore, it can be initially misidentified as a viridans group streptococcus and reported as a part of the normal flora. This may explain why so few cases are reported (8, 18, 20, 21) .
In most cases, the infections were successfully treated with antibiotic therapy, usually penicillin or amoxicillin associated with gentamicin (8) . Species isolated from clinical specimens in the past were usually sensitive to penicillin G and ampicillin. However, recent data suggest an emerging resistance. In 1993, a strain of G. haemolysans that was recovered from a blood culture was found to be sensitive to penicillin G, ampicillin, gentamicin, and cefuroxime and resistant to vancomycin, teicoplanin, erythromycin, and tetracycline (21). Our isolate was highly resistant to most of the antibiotics tested but sensitive to vancomycin, linezolid, and chloramphenicol.
In conclusion, although G. haemolysans is a rare pathogen in humans it may occasionally cause severe infections, including meningitis, endocarditis, and bacteremia, and while G. haemo- lysans is highly susceptible to many antibiotics, our data may show a possible increasing resistance rate.
